Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase 3 clinical trial for the treatment of Psoriasis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.
Metrics to compare | 068270 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship068270PeersSector | |
---|---|---|---|---|
P/E Ratio | 78.7x | 16.8x | −0.5x | |
PEG Ratio | −1.72 | 0.03 | 0.00 | |
Price / Book | 1.9x | 1.6x | 2.6x | |
Price / LTM Sales | 9.4x | 4.1x | 3.0x | |
Upside (Analyst Target) | 48.1% | 25.7% | 54.7% | |
Fair Value Upside | Unlock | 10.7% | 8.4% | Unlock |